Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

721.38
+31.164.52%
Number of Gainers:4
Number of Losers:- -
Number of Flat:- -
PE:- -
High:727.82
Open:694.18
Low:689.73
Close:690.21
Volume:45.05M
Turnover:721.09M
Market Cap:23.03B
Float Cap:17.76B

Loading ...

Crispr Therapeutics General Counsel James R. Kasinger Disposes of 1,990 Common Shares Worth $119,481.19

Reuters
·
Yesterday

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

GlobeNewswire
·
Oct 08

Top Recursion Pharma Insider Makes a Major Move With His Shares

TIPRANKS
·
Oct 08

Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today

TIPRANKS
·
Oct 08

Recursion Director Robert Hershberg Sells 25,000 Common Shares for $125,000

Reuters
·
Oct 08

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
Oct 08

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Tempus - Announces Expanded Multi-Year Collaboration for Intismeran Autogene Commercialization

THOMSON REUTERS
·
Oct 07

Tempus: to Also Provide Ngs Services to Support Intismeran Autogene Design and Manufacturing Process

THOMSON REUTERS
·
Oct 07

Tempus: to Manage Collection & Transfer of Tumor Tissue & Blood Samples Needed for Next-Generation Sequencing

THOMSON REUTERS
·
Oct 07

Tempus - Financial Terms of Collaboration not Disclosed

THOMSON REUTERS
·
Oct 07

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Oct 07

Personalis-Tempus AI Deal Clears US Antitrust Waiting Period Under HSR Act

Reuters
·
Oct 07

Personalis Slips as BTIG Downgrades, Sees no Rival Bid for Tempus Deal

Reuters
·
Oct 06

Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today

TIPRANKS
·
Oct 06

NASD Most Active Issues

Dow Jones
·
Oct 06

Tempus AI Inc Stock (TEM) Closed Up by 9.03% on Oct 5: Drivers Behind the Movement

TradingKey
·
Oct 06

Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?

Simply Wall St.
·
Oct 03

Beam Therapeutics (BEAM) Could Be 52% Undervalued Following Its Lawsuit Over Research Misuse

Simply Wall St.
·
Oct 03